Results 311 to 320 of about 1,254,012 (356)
Some of the next articles are maybe not open access.
Concordance index: Surrogacy of progression-free survival for overall survival
Contemporary Clinical Trials, 2021In oncology clinical trials, the primary endpoint is often time to an event of clinical interest, e.g., time to disease progression or time to death. As a result, progression-free survival (PFS: the time from initiation of treatment till disease progression or death whichever occurs first) and overall survival (OS: the time from initiation of treatment
Yiwei, Fan, Guosheng, Yin
openaire +2 more sources
Progression/Recurrence-Free Survival 2 in Adjuvant Melanoma
NEJM Evidence, 2022The long-term outcome of patients with stage III melanoma - that is, melanoma that has spread to nearby lymph nodes, lymphatics, or skin - who have received treatment with immune checkpoint inhibitors is of substantial interest. The article by Eggermont et al.1 published in this issue of NEJM Evidence reports 5-year outcomes from the stage III melanoma
Ryan C, Augustin, Jason J, Luke
openaire +2 more sources
Progression-Free Survival: Meaningful or Simply Measurable?
Journal of Clinical Oncology, 2012The last few years have seen an increase in the number of randomized controlled trials (RCTs) of new agents in metastatic solid tumors using progression-free survival (PFS) as the primary end point. Some trials showing improvement in PFS, without a correspondingincreaseinoverallsurvival(OS),haveledtoapprovalofnew drugs and/or changes in standard of ...
Christopher M, Booth +1 more
openaire +2 more sources
The Cancer Journal, 2009
In clinical trials of oncology drugs, overall survival (OS) is a direct measure of clinical efficacy and is considered the gold standard primary efficacy end point. The purpose of this study was to discuss the difficulties in using OS as a primary efficacy end point in the setting of evolving cancer therapies.
David, Lebwohl +4 more
openaire +2 more sources
In clinical trials of oncology drugs, overall survival (OS) is a direct measure of clinical efficacy and is considered the gold standard primary efficacy end point. The purpose of this study was to discuss the difficulties in using OS as a primary efficacy end point in the setting of evolving cancer therapies.
David, Lebwohl +4 more
openaire +2 more sources
Population kinetics of progression free survival (PFS).
Journal of Clinical Oncology, 2019e18251 Background: We assessed drug type impact on whether PFS curves could be fit by 2 phase decay models on nonlinear regression analysis (NLRA). Methods: We digitized 894 published PFS curves for incurable cancers. We used GraphPad Prism 7 for 1 phase and 2 phase decay NLRA, with constraints Y0 = 100 and plateau = 0. We defined curves as fitting 2
David J. Stewart +8 more
openaire +1 more source
Mitotic Index and Progression-Free Survival in Atypical Meningiomas
World Neurosurgery, 2020Extent of resection and tumor grade are considered the most important predictors of progression-free survival (PFS) in meningiomas. However, adjuvant therapy for atypical meningiomas remains controversial, with variable PFS rates of up to 40%. The current mitotic index (MI) range for atypical meningiomas is broad, comprising all tumors with >4 and
Ricardo A. Domingo +5 more
openaire +2 more sources
Sensitivity analysis of progression‐free survival with dependent withdrawal
Statistics in Medicine, 2008AbstractWe develop a sensitivity analysis method for comparing treatment‐specific distributions where the endpoint is progression‐free survival (PFS). The censoring process may be informative due to selective patient withdrawal, which occurs whenever disease evaluation has been discontinued without progression being documented. The sensitivity analysis
Ping K, Ruan, Robert J, Gray
openaire +2 more sources
Elacestrant Prolongs Progression-Free Survival in Advanced Breast Cancer
Cancer Discovery, 2022Abstract Prolonged progression-free survival was seen with elacestrant versus standard-of-care endocrine therapy.
openaire +2 more sources